17,261 trials
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
Huntington Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 46; 43; 49 Participants
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Multiple Myeloma
Primary: Efficacy of BCMA CAR-T Cell Therapy — 25; 13 Participants — p=<0.0001
Kidney Disease, Chronic
Primary: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 — 48.9; 16.0; 38.5; 11.4 Predicted percentage of…
Stroke, Ischemic
Primary: Number of Participants With Serious Adverse Events (SAEs) — 6; 10; 8 Participants
Knee Osteoarthritis
Primary: Change in Total BMD From Baseline in the Treated Knee Compared to Placebo by qCT — -0.47; -3.32 mg/cm^3
Ebola
Primary: Number of Participants With Solicited Adverse Events Following V920 Vaccination — 5; 1; 2; 1 Participants
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1]) — 51.9 percentage of participants
Clinical Stage IV Cutaneous Melanoma AJCC v8 · Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma
Primary: Clinical Benefit Rate (CBR) in PD-1 naïve Patients — 68.4 percentage of participants
Erythropoietic Protoporphyria
Primary: Percent Change From Baseline in Whole Blood Metal-free PPIX Levels — 8.07; -21.48; -41.74 Percent Change
Squamous Cell Carcinoma of the Head and Neck
Primary: Probability of Objective Response (OR) - Selected Treatment — 0 percentage of patients
Obesity
Primary: Part 1: Number of Treatment-emergent Adverse Events (TEAEs) — 56; 71; 37 Events
Anemia, Sickle Cell · Sickle Cell Disease
Primary: Percentage of Participants With Hemoglobin (Hb) Response — 15 Participants
Osteoarthritis (OA)
Primary: Change From Baseline in Cartilage Volume in the Index Region Measured by 7 Tesla MRI — 63.3; 49.8; 11.6 µL — p=0.2366